The first results of clinical studies of the drug "Favipiravir" claim that He can be the most effective in the treatment of COVID-19, told the online press conference, the Head of the Russian direct investment Fund Kirill Dmitriev.

in March, the Supervisory Board of the Fund has blessed the development of a joint venture with the group of companies "Chemrar" for the production of " Favipiravir ".

research of the drug is approved in Russia throughout Russia, with the participation of 330 patients.

He added, because it is confirmed by the Chinese clinical test, which showed that the drug reduces the duration of the disease from eleven days to four or five.

According to Dmitrieva, these results will reduce the load on medical centers as well as to minimize the number of epidemically dangerous patients presumably twice.

The head of Fund has noticed that the drug can be used only for the purpose and under the supervision of a physician, in addition, It is contraindicated during pregnancy.

"We hope to finish clinical trials by the end of this month," said Dmitriev.

Since the beginning of the epidemic in Russia has recorded 242 271 cases COVID-19, more than 43 thousand people infected have recovered, 2116 people have died.

The latest information on the situation of COVID-19 in Russia and the world presented on the portal stopmanager. Of the Russian Federation.



<span style="color:darkgray
sections: Politics